Company Profile:

DB Biotech was founded in 2006 and has since developed high quality antibodies used in research and routine clinical diagnostics. The main goal of the company is to introduce a new standard for the application of antibodies on a daily basis, from background-free western blots, to special quantitative diagnostics, or potential applications of humanized antibodies for disease treatment purposes.

DB Biotech is focused on the design and production of high quality rabbit clonal antibodies developed by a novel in-vitro cloning technology which is the original invention of the company. We are introducing a new level of quality of monospecific clonal antibodies that is characterized by an exceptional specificity, affinity and avidity.

The In-vitro cloning technology developed by DB Biotech enables the preparation of a pure immunoglobulin fraction corresponding to a single clone of B lymphocytes. The obtained immunoglobulin recognizes one single linear epitope on the antigen molecule; therefore this antibody is comparable quality-wise to its monoclonal analogue. Moreover, the influence of the protein tertiary structure – frequently present in epitopes formed during production of monoclonal antibodies – is eliminated in immunoglobulins corresponding to the clonal antibody. In this case, the produced antibody corresponds strictly to the conserved linear epitope of the antigen molecule.

DB Biotech is also offering custom services pertaining to the design and production of clonal antibodies against any protein or its modification whose name, detailed description of the modification or amino-acid sequences are supplied by the project contractor. We are actively participating in grant-funded research projects and welcome challenging requests from corporate clients.

DB Biotech is ISO 9001:2000 certified; we are also in preparation for ISO 13485:2003.
Our IHC antibodies have CE-IVD certification.